Clinical Trials Logo

Spasmodic Torticollis clinical trials

View clinical trials related to Spasmodic Torticollis.

Filter by:
  • None
  • Page 1

NCT ID: NCT03471923 Completed - Clinical trials for Nervous System Diseases

Non-Motor Features of Cervical Dystonia (CD)

Start date: March 26, 2018
Phase:
Study type: Observational

This study will examine the prevalence of four previously identified non-motor markers in a population of cervical dystonia patients, unaffected family members, and healthy volunteers in an attempt to identify a distinct combination of non-motor symptoms that may be indicative of disease development.

NCT ID: NCT01859247 Completed - Cervical Dystonia Clinical Trials

Identification of Optimal Stimulation Site for Cervical Dystonia Symptoms: An Exploratory Study

Start date: March 2013
Phase: N/A
Study type: Interventional

The overall objective of this application is to therapeutically target the dysfunctional premotor-motor interaction in dystonia—and to provide a focused treatment of specific anatomical networks in order to reduce side effects and to improve symptom control over conventional therapies.

NCT ID: NCT00549341 Completed - Clinical trials for Spasmodic Torticollis

PurTox (Botulinum Toxin Type A) for the Treatment of Adult Onset Spasmodic Torticollis/Cervical Dystonia

Start date: May 2006
Phase: Phase 1
Study type: Interventional

The safety and efficacy of Mentor Purified Toxin, Botulinum Toxin Type A, Purified Neurotoxin, injected intramuscularly into the neck, is being evaluated as a treatment for painful and non-painful spasmodic torticollis/cervical dystonia. It is hypothesized that treatment will decrease symptom severity and will not have any significant side effects.

NCT ID: NCT00528541 Completed - Clinical trials for Spasmodic Torticollis

Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Type A in Moderate to Severe Cervical Dystonia

Start date: September 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare two types of botulinum toxin type A to treat the involuntary muscle contractions in the neck

NCT ID: NCT00432341 Terminated - Clinical trials for Spasmodic Torticollis

Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Moderate to Severe Cervical Dystonia

Start date: June 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare two types of botulinum toxin type A to treat the involuntary muscle contractions in the neck

NCT ID: NCT00280384 Completed - Clinical trials for Spasmodic Torticollis

An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian Subjects

Start date: January 2006
Phase: Phase 2
Study type: Interventional

To evaluate inter-ethnic similarity in pharmacodynamics between Japanese and Caucasian healthy adult male subjects by comparing electrophysiological reactions after administering E2014 to extensor digitorum brevis muscle (EDB).

NCT ID: NCT00210431 Completed - Cerebral Palsy Clinical Trials

Post Marketing Surveillance Study of Dysport

Start date: October 2004
Phase:
Study type: Observational

The purpose of this study is to provide further information regarding the risks and benefits of Dysport in marketed indications.

NCT ID: NCT00165776 Completed - Cervical Dystonia Clinical Trials

Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic Torticollis

Start date: June 2004
Phase: Phase 2
Study type: Interventional

To evaluate efficacy and safety of E2014 (2500U, 5000U, 10000U, placebo) in a multicenter, randomized, double-blind, parallel group comparative study by intramuscularly administering to patients with spasmodic torticollis. Primary endpoint for efficacy evaluation is changes in TWSTRS total scores from baseline measured at Week 4 and the clinical recommended dose will be examined with Williams multiple comparison. For safety evaluation, an inter group comparison (active drug and placebo) will be performed mainly focusing on incidence of adverse events, adverse drug reactions, and abnormal changes in laboratory parameters.